Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7009 intravenous infusion for conversion of atrial fibrillation
2005-000204-13Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of azd7009 in Atrial fibrillation (AFib) (3 arms), sponsored by AstraZeneca. Primary endpoint: Efficacy of AZD7009 vs placebo in conversion of atrial fibrillation. Started Feb 2005; status: completed.
02
Drugs
azd7009
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2005-000204-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000204-13.